Through a randomized controlled trial (RCT) design, this study aiming to evaluated the efficacy and safety of rituximab lymph node injection combined with pulmonary vascular interventional therapy in treating fibrosing mediastinal pulmonary hypertension (FM-PH).Eligible participants were randomly assigned to either the combined treatment group, receiving both pulmonary vascular intervention and rituximab lymph node injection, or the interventional-only group, which received pulmonary vascular intervention alone. At 3, 6, and 12 months post-treatment, the efficacy was assessed based on symptom improvement, hemodynamic changes, lesion volume reduction, etc. Safety was mainly evaluated by comparing adverse event incidence between the two groups.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
48
Based on the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed vessels. During the treatment cycle, one lymph node drug injection is administered: 50mg of rituximab is dissolved in 15ml of 5% glucose solution and injected at multiple sites into the identified enlarged mediastinal lymph nodes under ultrasound-guided bronchoscopy.
According to the degree of vascular stenosis, individualized and periodic pulmonary vascular interventions are performed to reopen obstructed pulmonary vessels.
Beijing Chaoyang Hospital, Capital Medical University
Beijing, China
RECRUITINGChange from Baseline in the Six Minutes Walk Distance at 12 Months.
Conduct 6-minute walk test to measure the 6-minute walk distance, and compare the walking distances at baseline and 12 months after treatment.
Time frame: From enrollment to the end of treatment at 12 months
The incidence of treatment-related serious adverse events (SAE)
The incidence of treatment-related serious adverse events is measured by tracking and documenting any SAEs that occur during the treatment period, as well as through follow-up assessments. Each event is evaluated for severity and causality, and the incidence is calculated by dividing the number of patients who experience at least one treatment-related SAE by the total number of treated patients.
Time frame: During the one-year follow-up period after treatment completion
Change from baseline in the World Health Organization Functional Classification of Pulmonary Hypertension at 3, 6 and 12 months.
Change from Baseline in the World Health Organization Functional Classification of Pulmonary Hypertension (WHO-FC) which assessed based on clinical symptoms and signs at baseline and the end of treatment at 3, 6 and 12 months. The WHO-FC system consists of four levels: I, II, III, and IV. Higher levels indicate progressively more severe conditions.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months.
Change from Baseline in the mean pulmonary artery pressure (mPAP) at 3 and 12 Months.
The mean pulmonary artery pressure (mPAP) was measured by right heart catheterization to evaluate the hemodynamic change from baseline to the end of treatment at 3 and12 months.
Time frame: From enrollment to the end of treatment at 3 and12 months
Change from Baseline in the Cardiac Index (CI) at 3 and 12 Months.
The Cardiac Index (CI) was measured by right heart catheterization to evaluate the hemodynamic change from baseline to the end of treatment at 3 and12 months.
Time frame: From enrollment to the end of treatment at 3 and12 months
Change from Baseline in the Pulmonary Vascular Resistance (PVR) at 3 and 12 Months.
The Pulmonary Vascular Resistance (PVR) was measured by right heart catheterization to evaluate the hemodynamic change from baseline to the end of treatment at 3 and12 months.
Time frame: From enrollment to the end of treatment at 3 and12 months
Change from Baseline in the forced vital capacity (FVC) at 3, 6 and 12 Months.
Pulmonary function tests was performed, including the forced vital capacity (FVC), to evaluated pulmonary function at baseline and the end of treatment at 3, 6 and 12 Months.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months
Change from Baseline in the forced vital capacity of predicted (FVC%pred) at 3, 6 and 12 Months.
Pulmonary function tests was performed, including the forced vital capacity of predicted (FVC%pred), to evaluated pulmonary function at baseline and the end of treatment at 3, 6 and 12 Months.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months
Change from Baseline in the forced expiratory volume in 1 second (FEV1) at 3, 6 and 12 Months.
Pulmonary function tests was performed, including the forced expiratory volume in 1 second (FEV1), to evaluated ventilation function at baseline and the end of treatment at 3, 6 and 12 Months.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months
Change from Baseline in the forced expiratory volume in 1 second of predicted (FEV1%pred) at 3, 6 and 12 Months.
Pulmonary function tests was performed, including the forced expiratory volume in 1 second of predicted (FEV1%pred), to evaluated ventilation function at baseline and the end of treatment at 3, 6 and 12 Months.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months
Change from Baseline in the FEV1/FVC ratio at 3, 6 and 12 Months.
Pulmonary function tests was performed, including the FEV1/FVC ratio, to evaluated ventilation function at baseline and the end of treatment at 3, 6 and 12 Months.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months
Change of the BNP/NT-Pro BNP from baseline to the end of treatment at 3, 6 and 12 months.
The BNP/NT-Pro BNP will be measured at baseline the end of treatment at 3, 6 and 12 months to evaluate the condition of heart failure.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months.
The restenosis rate of blood vessels after interventional therapy at the end of treatment at 3 and 12 months
Restenosis following interventional therapy was monitored at the end of treatment at 3 and 12 months, with restenosis defined as a blood vessel diameter reduction of more than 50% from the original size, or when the pressure gradient (Pd) at the site of vascular stenosis increases by 5 mmHg or more compared to the last measurement.
Time frame: From enrollment to the end of treatment at 3 and 12 months.
Change of the mediastinal lesion volume from baseline to 3 and 12 months after the end of treatment.
The mediastinal lesion volume will be measured at baseline and 3, 12 months after the end of treatment using CTPA or PET-CT imaging. The volume is represented by the maximum transverse diameter of the cross-section of the lesion site.
Time frame: From enrollment to the end of treatment at 3 and12 months.
Change from baseline of the quality-of-life score at 3, 6 and 12 months after the end of treatment.
Quality of life was assessed using the 36-Item Short-Form Health Survey (SF-36) at baseline and 3, 6 and 12 months after the end of treatment. The SF-36 scoring scale consists of 8 dimensions, which can be summarized as physical health and mental health. The score range of each dimension is 0 to 100 points. The higher the score, the better the health condition.
Time frame: From enrollment to the end of treatment at 3, 6 and 12 months
Number of participants with complications of bronchoscopy and pulmonary intervention.
Measure the probability of complications occurring during or after therapeutic operations. Complications of pulmonary vascular intervention include pulmonary vascular injury, arrhythmia, reperfusion pulmonary edema, etc; Complications of bronchoscopy include pneumothorax, massive hemoptysis, infection, etc.
Time frame: Immediately or in the short term after treatment, and within 12 months after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.